MRUSMerus N.V.

Nasdaq merus.nl


$ 59.13 $ -1.03 (-1.71 %)    

Friday, 28-Jun-2024 15:59:54 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 59.17
$ 60.21
$ 59.14 x 300
$ 0.00 x 0
$ 58.33 - $ 61.07
$ 19.81 - $ 61.61
1,345,448
na
3.44B
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-merus-maintains-92-price-target

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $92 price target.

 citigroup-maintains-buy-on-merus-raises-price-target-to-93

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $70 to $93.

 b-of-a-securities-maintains-buy-on-merus-maintains-76-price-target

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and maintains $76 price target.

 stifel-maintains-buy-on-merus-raises-price-target-to-99

Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $90 to $99.

 b-of-a-securities-maintains-buy-on-merus-lowers-price-target-to-76

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $80 to $76.

 bmo-capital-maintains-outperform-on-merus-raises-price-target-to-91

BMO Capital analyst Etzer Darout maintains Merus (NASDAQ:MRUS) with a Outperform and raises the price target from $84 to $91.

 truist-securities-maintains-buy-on-merus-raises-price-target-to-88

Truist Securities analyst Asthika Goonewardene maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $69...

 merus-mcla-129-demonstrates-single-agent-efficiency-in-metex14-nsclc-in-poster-presentation-at-asco-2024

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...

 merus-presented-interim-data-on-mcla-145-monotherapy-and-in-combination-with-pembrolizumab-at-asco-2024

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...

 reported-earlier-merus-prices-upsized-public-offering-of-755m-common-shares-at-53share

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses a...

 b-of-a-securities-maintains-buy-on-merus-raises-price-target-to-80

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $61 to $80.

 hc-wainwright--co-maintains-buy-on-merus-raises-price-target-to-85

HC Wainwright & Co. analyst Andrew Fein maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to...

 needham-maintains-buy-on-merus-raises-price-target-to-92

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $66 to $92.

 guggenheim-maintains-buy-on-merus-raises-price-target-to-93

Guggenheim analyst Michael Schmitz maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $57 to $93.

 stifel-maintains-buy-on-merus-raises-price-target-to-90

Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to $90.

 merus-reveals-interim-results-for-bispecific-antibody-petosemtamab-with-pembrolizumab-at-2024-american-society-of-clinical-oncology-annual-meeting

 Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-lengt...